Steven Pfanstiel News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Steven pfanstiel. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Steven Pfanstiel Today - Breaking & Trending Today

Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) Q3 2023 Earnings Call Transcript

Operator: Greetings and welcome to the Marinus Pharmaceuticals Third Quarter 2023 Financial Results and Business Update Call. [Operator Instructions]. ....

United States , Joseph Hulihan , Daniel Gossett , Steven Pfanstiel , Scott Braunstein , Brian Abrahams , Christy Shafer , Christina Shafer , Joe Hulihan , Thomas Lyons , Joseph Thome , Steve Pfanstiel , Sonya Weigle , Marinus Pharmaceuticals Inc , American Epilepsy Society Meeting , Orion Corporation , Exchange Commission , Marinus Access Program , Part Of Uniphar Group Product Access Division , American Epilepsy Society Annual Meeting , Corporate Affairs , Marinus Pharmaceuticals , Call Transcript November , Marinus Pharmaceutical Third Quarter , Business Update , Senior Vice President ,

Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) Q3 2023 Earnings Call Transcript

Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) Q3 2023 Earnings Call Transcript November 7, 2023 Marinus Pharmaceuticals, Inc. beats earnings expectations. Reported EPS is $-0.61, expectations were $-0.67. Operator: Greetings and welcome to the Marinus Pharmaceuticals’ Third Quarter 2023 Financial Results and Business Update Call. [Operator Instructions]. And now, it is my pleasure to introduce your host, Sonya […] ....

United States , Steven Pfanstiel , Joe Hulihan , Joseph Hulihan , American Epilepsy Society Meeting , American Epilepsy Society Annual Meeting , Marinus Access Program , Marinus Access , Chief Medical Officer , American Epilepsy Society , Lennox Gastaut Syndrome , Undervalued Dividend Stocks To Buy Now , Dividend Stocks ,

Marinus Pharmaceuticals (MRNS) Scheduled to Post Earnings on Tuesday

Marinus Pharmaceuticals (NASDAQ:MRNS – Get Free Report) is set to release its earnings data before the market opens on Tuesday, November 7th. Analysts expect Marinus Pharmaceuticals to post earnings of ($0.67) per share for the quarter. Persons that wish to listen to the company’s earnings conference call can do so using this link. Marinus Pharmaceuticals […] ....

Scott Braunstein , Robertw Baird , Steven Pfanstiel , Earnings History For Marinus Pharmaceuticals , Marinus Pharmaceuticals Stock Performance , Securities Exchange Commission , Royal Bank , Marinus Pharmaceuticals , Institutional Trading Of Marinus Pharmaceuticals , Marinus Pharmaceuticals Inc , Ameritas Investment Partners Inc , News Ratings For Marinus Pharmaceuticals Daily , Get Free Report , Exchange Commission , Investment Partners , Exoduspoint Capital Management , Marinus Pharmaceuticals Daily , Nasdaq Mrns ,

Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) Receives $21.50 Consensus Price Target from Brokerages

Shares of Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS – Get Free Report) have been assigned a consensus recommendation of “Moderate Buy” from the nine research firms that are presently covering the stock, Marketbeat Ratings reports. One equities research analyst has rated the stock with a hold recommendation and eight have issued a buy recommendation on the company. […] ....

Robertw Baird , Scott Braunstein , Steven Pfanstiel , Life Insurance Co , Securities Exchange Commission , Marinus Pharmaceuticals Inc , Marinus Pharmaceuticals Stock Performance , Royal Bank , Ameritas Investment Partners Inc , Marinus Pharmaceuticals , News Ratings For Marinus Pharmaceuticals Daily , Institutional Investors Weigh In On Marinus Pharmaceuticals , Cantor Fitzgerald , Analyst Recommendations For Marinus Pharmaceuticals , Marinus Pharmaceuticals Company Profile , Get Free Report , Marketbeat Ratings , Exchange Commission , Investment Partners , Jane Street Group , Get Free , Marinus Pharmaceuticals Daily , Nasdaq Mrns ,

Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) Receives $21.50 Average Price Target from Analysts

Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) Receives $21.50 Average Price Target from Analysts
theenterpriseleader.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from theenterpriseleader.com Daily Mail and Mail on Sunday newspapers.

Steven Pfanstiel , Scott Braunstein , Robertw Baird , Insider Transactions At Marinus Pharmaceuticals , Marinus Pharmaceuticals Stock Performance , Mirabella Financial Services , Institutional Investors Weigh In On Marinus Pharmaceuticals , Opaleye Management Inc , News Ratings For Marinus Pharmaceuticals Daily , Asset Management Inc , Marinus Pharmaceuticals , Denali Advisors , Marinus Pharmaceuticals Inc , Capital Corp , Analyst Recommendations For Marinus Pharmaceuticals , Royal Bank , Get Free Report , Asset Management , Financial Services , Get Free , Marinus Pharmaceuticals Daily ,